Top-News
  • Depot
  • Watchlist
  • Glocke
  • Handeln

    • Abliva News

    0,0079 € -1,25% -0,0001 €
    11:21:45 Uhr Frankfurt aktualisieren | Orderbuch | Mehr Kurse »
    WKN: A0X93Z
    ISIN: SE0002575340
    US-Symbol: NEVPF
    Typ: Aktie

    Abliva News

    26.06.20 - DGAP
    Edison Investment Research Limited: Edison issues update on Abliva (NVP)
    Edison Investment Research Limited Edison Investment Research Limited: Edison issues update on Abliva (NVP) 26-Jun-2020 / 12:41 GMT/BST London, UK, 26 June 2020 ...
    19.02.20 - PR Newswire
    NeuroVive Pharmaceutical AB Year End Report January - December 2019
    NeuroVive Pharmaceutical AB Year End Report January - December 2019 PR Newswire
    19.02.20 - PR Newswire
    NeuroVive Pharmaceutical AB Year End Report January - December 2019
    NeuroVive Pharmaceutical AB Year End Report January - December 2019 PR Newswire
    20.12.19 - PR Newswire
    NeuroVive Completes Recruitment in the Second Part of its Ongoing KL1333 Clinical Phase Ia/b Study
    NeuroVive Completes Recruitment in the Second Part of its Ongoing KL1333 Clinical Phase Ia/b Study PR Newswire
    20.12.19 - PR Newswire
    NeuroVive Completes Recruitment in the Second Part of its Ongoing KL1333 Clinical Phase Ia/b Study
    NeuroVive Completes Recruitment in the Second Part of its Ongoing KL1333 Clinical Phase Ia/b Study PR Newswire
    16.12.19 - PR Newswire
    NeuroVive Announces Settlement in Dispute With CicloMulsion AG
    NeuroVive Announces Settlement in Dispute With CicloMulsion AG PR Newswire
    16.12.19 - PR Newswire
    NeuroVive Announces Settlement in Dispute With CicloMulsion AG
    NeuroVive Announces Settlement in Dispute With CicloMulsion AG PR Newswire
    20.11.19 - PR Newswire
    NeuroVive Pharmaceutical AB Interim Report January - September 2019
    NeuroVive Pharmaceutical AB Interim Report January - September 2019 PR Newswire
    20.11.19 - PR Newswire
    NeuroVive Pharmaceutical AB Interim Report January - September 2019
    NeuroVive Pharmaceutical AB Interim Report January - September 2019 Continued Progress in KL1333 PR Newswire
    21.08.19 - PR Newswire
    NeuroVive Pharmaceutical AB Interim Report January - June 2019
    NeuroVive Pharmaceutical AB Interim Report January - June 2019 PR Newswire
    21.08.19 - PR Newswire
    NeuroVive Pharmaceutical AB Interim Report January - June 2019
    NeuroVive Pharmaceutical AB Interim Report January - June 2019 Focus on genetic mitochondrial diseases PR Newswire
    20.08.19 - PR Newswire
    Save the Date: NeuroVive to host Capital Markets Day in Stockholm on 9 October, 2019
    Save the Date: NeuroVive to host Capital Markets Day in Stockholm on 9 October, 2019 PR Newswire
    27.07.19 - PR Newswire
    NeuroVive's NeuroSTAT Project Receives FDA Fast Track Designation
    NeuroVive's NeuroSTAT Project Receives FDA Fast Track Designation PR Newswire
    27.07.19 - PR Newswire
    NeuroVive's NeuroSTAT Project Receives FDA Fast Track Designation
    NeuroVive's NeuroSTAT Project Receives FDA Fast Track Designation PR Newswire
    04.07.19 - PR Newswire
    NeuroVive Initiates Second Part of its Ongoing KL1333 Phase Ia/b Clinical Study
    NeuroVive Initiates Second Part of its Ongoing KL1333 Phase Ia/b Clinical Study PR Newswire
    04.07.19 - PR Newswire
    NeuroVive Initiates Second Part of its Ongoing KL1333 Phase Ia/b Clinical Study
    NeuroVive Initiates Second Part of its Ongoing KL1333 Phase Ia/b Clinical Study PR Newswire
    21.05.19 - PR Newswire
    NeuroVive Pharmaceutical AB Interim Report January - March 2019
    NeuroVive Pharmaceutical AB Interim Report January - March 2019 First subjects enrolled in the KL1333 study PR Newswire
    10.05.19 - PR Newswire
    NeuroVive's IND for Clinical Development of NeuroSTAT Approved by FDA
    NeuroVive's IND for Clinical Development of NeuroSTAT Approved by FDA PR Newswire
    10.05.19 - PR Newswire
    NeuroVive's IND for Clinical Development of NeuroSTAT Approved by FDA
    NeuroVive's IND for Clinical Development of NeuroSTAT Approved by FDA PR Newswire
    25.03.19 - PR Newswire
    NeuroVive Pharmaceutical AB Publishes 2018 Annual Report
    NeuroVive Pharmaceutical AB Publishes 2018 Annual Report PR Newswire

    Newssuche

    Videos

    newspaper
    26.04.24 -5,94%
    Technical Trading: Gold Long freitags
    Gold Long Typ: Turbo Open End WKN: NG8DB8 Hebel: 27 Laufzeit: OpenEnd Einstieg: Market ... Mehr »